Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Shareholder Meeting (November 2012)
31 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 22, 2012
Slide 1: Harnessing Biodiversity for Peptide Therapies
For personal use only Harnessing Biodiversity for Peptide Therapies Dr Paul Wa), CEO Nick Woolf, CFO & VP Corporate Development AGM, 22 November 2012 1
Slide 2: Disclaimer
Disclaimer The purpose of the presentation is to provide an update of the business of Phylogica Limited For personal use only (ASX:PYC) [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc
Slide 3: 2012 highlights
2012 highlights For personal use only ! Signed alliance with Janssen Biotech – our biggest and broadest deal to-‐date ! Achieved Pfizer discovery milestone in therapeuFc vaccine collaboraFon ! Progressed our alliances with Roche/Genentech and MedImmune ! Upgraded scale and capabiliFes of Phylomer di
Slide 4: Phylogica's current partnerships span a wide range of areas
Phylogica’s current partnerships span a wide a range of areas For personal use only Cell penetrating peptides Phylogica CNS Delivery Antimicrobials Vaccines 4 4 4
Slide 5: Phylomer Platform
4 For personal use only 5 Phylomer Platform
Slide 6: Rapid growth in peptide drug market
Rapid growth in peptide drug market ! For personal use only Pep=des are one of fastest growing drug classes § 60 marketed pepFdes represent $13 billion market § PepFde market growing twice as fast as small molecules § New technologies are addressing tradiFonal pepFde challenges (eg: stability, ha
Slide 7: Phylomers derive from parts of biodiverse proteins
Phylomers derive from parts of biodiverse proteins § Encoded from >35 biodiverse bacterial genomes, environments like volcanos, geysers For personal use only and undersea vents § Phylomer libraries now contain 126 billion disFnct pepFde sequences § Pre-‐selected by evoluFon to allow survival, su
Slide 8: Bacteria provide richest source of diversity
Bacteria provide richest source of diversity For personal use only ! World’s richest source of diverse natural secondary and terFary structures 8 Wa2 PM (2006), Nature Biotechnology, Vol 24 (2):177-‐83
Slide 9: Phylomers: a powerful toolbox for drug discovery
Phylomers: a powerful toolbox for drug discovery For personal use only Intracellular Targets Extracellular Targets Phenotypic Antimicrobial Screening Phylomers Epitope Mapping Scaffold Discovery Novel Cell Penetrating Peptides Vaccines 9
Slide 10: Cell penetrating Phylomers: gaining access to intracellular targets
Cell penetrating Phylomers: gaining access to intracellular targets For personal use only Phylomer CPPs Extracellular Druggable Targets 20% 80% Antibodies Small Molecules (10%) Scaffolds Small Molecules Phylomers Extracellular targets Intracellular targets • CPPs can expand the druggable landscape b
Slide 11: Phylomers can have intrinsic cell penetrating activity
Phylomers can have intrinsic cell penetrating activity ! Phylomers engage natural processes to penetrate cells ! We can use Phylomers to deliver drugs into cells (PDC) For personal use only Ovarian cells 11
Slide 12: Capturing a natural virulence factor evolved for cell penetration
Capturing a natural virulence factor evolved for cell penetration Fibronectin enhances delivery HUVECS (fixed) For personal use only FITC/DAPI DAPI FITC BEN_1312 FITC/DAPI/Integrin Integrin 𝛼5𝛽1 Fibronectin binding peptide co-localises with Integrin receptor 12
Slide 13: Strategy to realise shareholder value
For personal use only Strategy to realise shareholder value 13
Slide 14: Three overlapping strategic phases
Three overlapping strategic phases 1. PARTNERING (2012/2013): Short term revenue growth from Pharma fee-for-service For personal use only alliances 2. TECHNOLOGICAL LEADERSHIP (2013/2014): Building capital value by enhancing Phylomer drug discovery platform 3. PRODUCTS AND POSITIONING (2014/2015): P
Slide 15: Growing the capital value while growing revenue streams
For personal use only Growing the capital value while growing revenue streams Potential to grow revenues over time Potential to grow capital value over time ! Pharma revenue provides a useful and non-dilutive way to subsidise asset development ! Pharma alliances build accumulating stake in downstrea
Slide 16: The main game: what do the acquirers value most?
The main game: what do the acquirers value most? Biologics library companies are valued for the impact of their discovery platform and products on the future pipeline of acquirer For personal use only ! Plan to exit via a trade sale to big pharma company or a specialist pharma/biotech ! No correlati
Slide 17: What does the ideal library acquisition candidate look like?
What does the ideal library acquisition candidate look like? ! Has validated its drug lead discovery engine against multiple targets For personal use only ! Technology addresses unmet needs not addressed by other approaches (small molecules, antibodies, conventional peptides, protein scaffolds) ! Ha
Slide 18: Strategic Scorecard: phase 1st
For personal use only Strategic Scorecard: 1 phase st 18
Slide 19: Maximising near-term revenue
For personal use only Maximising near-term revenue Revenue Streams ! Generate near-term revenue from fee-for-service drug discovery alliances ! Seek partners for internal assets: § Neuroprotective Phylomers § Antimicrobial Phylomers § Phylomer for UV/thermal burns (Le Metier de Beauté) § CD40 li
Slide 20: Four pharma partnerships in three years
Four pharma partnerships in three years ! Roche/Genentech For personal use only § CollaboraFon to discover brain delivery pepFdes in December 2009 § Expanded to discover pepFdes that cross blood-‐brain barrier in May 2011 ! MedImmune (AstraZeneca) § CollaboraFon to discover anFbioFc pepFdes in A
Slide 21: Specialisation is paying off!
For personal use only Specialisation is paying off! Cell penetrating peptides Phylogica CNS Delivery Antimicrobials Vaccines 21 21
Slide 22: Extensive pipeline of partnering opportunities
Extensive pipeline of partnering opportunities ! Progressing >25 discussions with prospec=ve or exis=ng partners on new deals For personal use only § Four prospects at stage of term-‐sheet or contractual negoFaFons Phylomer Platform In-House Activities & Partnerships No. of Deal Opportunity Discus
Slide 23: Pharma interest continues to be real and tangible
For personal use only Pharma interest continues to be real and tangible 31 October 2012 “Our scientists were delighted to meet you and inspired Platform by your presentation. They Enhancements would like to consider Our competitive edge requires ongoing the collaboration. Theyinvestment will draft o
Slide 24: Strategic Scorecard: phase 2nd
For personal use only Strategic Scorecard: 2 phase nd 24
Slide 25: Internal platform development
For personal use only Internal platform development ! Investment in platform required to retain technological leadership ! Improvements allow significant value enhancements for partners & PYC ! Build next generation libraries to renew Phylogica’s core IP ! Accelerate screening against internal targe
Slide 26: Delivering on platform upgrades
For personal use only Delivering on platform upgrades ! Successfully enhanced efficiency and capacity of Phylomer platform § Commissioned upgraded screening facility including advanced robotics § Upgraded libraries by 47-fold to total complexity of >126 billion individual Phylomers § Validated di
Slide 27: Corporate Summary
For personal use only 27 Corporate Summary
Slide 28: Financial snapshot
Financial snapshot ! ASX =cker: PYC For personal use only ! Market cap: circa $10 million ! Revenue FY2012: $2 million ! Capital raising October 2012: $1.6 million ! R&D Tax Credit received October 2012: $1.9 million ! Pro forma net cash posi=on 30 September 2012: $4.9 million ! Cash burn FY2012: $4
Slide 29: What is unique about the Phylomer platform
For personal use only What is unique about the Phylomer platform Phenotypic Screening Phylomer Libraries Blocking Intracellular Discovery of specific Cell Protein/protein InteracRons PenetraRng PepRdes Phylogica has developed an integrated discovery platform to: ! Discover and validate new therapeuti
Slide 30: Summary
Summary ! Assembled world-‐class pepFde drug discovery plaLorm For personal use only ! Successfully validated ‘Alliance Model’ with four partnerships ! Delivering on collaboraFve discovery objecFves for exisFng Pharma partners ! Upgrading screeening capabiliFes and Phylomer libraries for maximum co
Slide 31: Contact Details
Contact Details Dr. Paul Wa) Nick Woolf Chief Execu=ve Officer CFO, VP Corporate Development Tel: +61 8 9489 7777 Tel: +61 8 9489 7777 Fax: +61 8 9489 7700 For personal use only Fax: +61 8 9489 7700 Mobile: +61 421 550 213 Mobile: +61 417 986 005 paulw@phylogica.com nwoolf@phylogica.com www.phylogica.